| Title: | A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. |
| authorizations: |
registration not required
|
| accessURL: |
http://www.iedb.org/reference/1009511 |
| landingPage: |
http://www.iedb.org/assay/1931493 |
| type: |
Literature
|
| publicationVenue: |
Proteomics
|
| dates: |
2002
|
| study type: | b cell assays |
| subject species: | Pseudomonas sp. RS-16 |
| fullName: |
Daniel I R Spencer
Lynda Robson
Des Purdy
Nick R Whitelegg
N Paul Michael
Jeetendra Bhatia
Surinder K Sharma
Anthony R Rees
Nigel P Minton
Richard H J Begent
Kerry A Chester
|
| method: |
cross blocking
|
| name: |
A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics.
|
| description: |
The epitope-specific scFv CM79 partially blocked (up to 18%) the binding to CPG2 by human antibodies from patients treated with A5B7-CPG2 antibody-enzyme conjugates. Single alanine substitution of residue R162 reduced binding of 11 patient sera by 19 to 62%, indicating this is a critical residue for human antibodies to CPG2 induced by CPG2 conjugate therapy.
|
| name: |
iedb
|
| homePage: |
http://www.iedb.org |